Form 8-K Replimune Group, Inc For: Dec 05 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Replimune (REPL) study of RP1 in combination with cemiplimab did not meet either of the two primary endpoints streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Replimune Group said on
Tuesday its experimental drug to treat a common form of skin
cancer did not meet the main goals in a late-stage study.
(Reporting by Mariam Sunny in Bengaluru; Editing by.
(Reuters) - Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove .